Ciloxan Eye & Ear Drops 0.3% 3 mg/ml

Country: Jordan

Language: English

Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Active ingredient:

Ciprofloxacin 3 mg/ml

Available from:

مستودع أدوية الحديثة - Modern Drug Store

ATC code:

S01AX13

INN (International Name):

Ciprofloxacin 3 mg/ml

Dosage:

3 mg/ml

Units in package:

5 ml

Manufactured by:

S.A Alcon couvreur N.V Rijksweg (بلجيكا)

Product summary:

2.03 :سعر الجمهور + الضريبة

Patient Information leaflet

45374-1
IIIIIIIIIIIIIII111I
I
CILOXAN®
3 mg/mf, eye and ear drops. solution
1.
NAME
OF
THE
MEOICINAL
PRODUCT
CILOXAN'.3
mglml.
eye
and
ear
drops,
soltrllen.
2.
QUAUTATIVE
AND
QUANTITATIVE
COMPOSITION
Ciproflo,aGIn
hydrochloride
3.5
mglmllequlv. 3
mglml
base)
for
excipients,
see
6.1
3,
PHARMACEUTICAL
FORM
Eye
and
ear
drops,
solution.
4,
CLINICAL
PARTICULARS
4,1
Therapeullc
indications
CllOXAN€
'
is
Indicated
In
the
treatment
of
corneal
ulcers
and
supertiG,,1
infections
of
the
eye
and
ils
adnexa,
caused
by
slrains
presumed
or
reported
slJsceptible
to
clprofloxacin,
in
specific
_Pseudomonas _
_aeruginosa _
and
other
gram-negative
organisms
resistant
to
common
treatments.
CILOXAN2,
is
a/so
iM/cated
_for _
a
iDea!
or
diffuse
01itis
extema
accompanied
by
a
strong
Inilammatory
reaction
caused
by
strains
thai
me
susceptIble
to
ciprotloxacin.
as
for
a
sudden
flare-up
of
a
chronic
otitis
media.
In
this
case,
a
mucopurulent
secretion
passes
through
1110
periorated
eardrum.
_Pseudomonas _
_aeruginosa _
is
one
of
the
mosl1!kely
Ofganisms
to
be
found
here.
Also
in
case
of
other
ear
inflammations
in
which
_Pseudomonas _
_aeruginosa _
and
lor
other
susceptible
germs
(e.g.
in
the
case
of
suppurating
tympanic
tubes)
may
be
demonslrated
or
suspected,
CILOXAN
0
can
be
used
under
the
slriCI
supervision
of
an
ear
specialist.
One
sllould
realise
that
II
does
not
inVOlVe
a
routine
treatment
here,
so
improper
use
must
be
aVOided.
4.2
Posology
and
method
of
administration
CQ!ll!l.i!!.J1l,-~
CILOXAN"
must
be
admlnislered
in
lhe
follOWing
Inlervals,
even
during
nighl
time:
On
Ihe
1st
day:
IO$lil2
drops
inlo
the
affecled
eye
every
15
minutes
for
Ihe
first
six
hours;
and
then
2
drops
inlo
the
affecled
eye
every
30
minutes
for
the
remainder
of
the
day.
On
the
2nd
day:
instil
2
drops
into
the
affected
eye
hourly.
On
the
3rd
through
Ihe
14th
day,
put
tNO
drops
in
the
affected
eye
every
4
hours.
If
treatment
is
10
surpass
14
days,
the
quanlities
canile
adapted
to
the
wiShes
of
the
aHending
physician.
SuperficiilLbllC.Jilllil!
infec.tiQm;Jl!Jhe